KILR CD16 Effector Cells are purified human cytotoxic T lymphocytes stably expressing CD16 (FcɣRIIIa; V158 variant), produced in a standardized batch. The cells were developed for antibody-dependent cell-mediated cytotoxicity (ADCC) applications where low lot-to-lot variability is required, such as lot release of therapeutic antibodies.